Cargando…
oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow
oxLDL peptide vaccine and its antibody adoptive transferring have shown a significantly preventive or therapeutic effect in atherosclerotic animal model. The molecular mechanism behind this is obscure. Here, we report that oxLDL induces MCP‐1 release in monocytes/macrophages through their TLR‐4 (Tol...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387129/ https://www.ncbi.nlm.nih.gov/pubmed/27995732 http://dx.doi.org/10.1111/jcmm.13033 |
_version_ | 1782520884486995968 |
---|---|
author | Su, Jinyu Zhou, Hui Liu, Xianyan Nilsson, Jan Fredrikson, Gunilla Nordin Zhao, Ming |
author_facet | Su, Jinyu Zhou, Hui Liu, Xianyan Nilsson, Jan Fredrikson, Gunilla Nordin Zhao, Ming |
author_sort | Su, Jinyu |
collection | PubMed |
description | oxLDL peptide vaccine and its antibody adoptive transferring have shown a significantly preventive or therapeutic effect in atherosclerotic animal model. The molecular mechanism behind this is obscure. Here, we report that oxLDL induces MCP‐1 release in monocytes/macrophages through their TLR‐4 (Toll‐like receptor 4) and ERK MAPK pathway and is calcium/potassium channel‐dependent. Using blocking antibodies against CD36, TLR‐4, SR‐AI and LOX‐1, only TLR‐4 antibody was found to have an inhibitory effect and ERK MAPK‐specific inhibitor (PD98059) was found to have a dramatic inhibitory effect compared to inhibitors of other MAPK group members (p38 and JNK MAPKs) on oxLDL‐induced MCP‐1 release. The release of cytokines and chemokines needs influx of extracellular calcium and imbalance of efflux of potassium. Nifedipine, a voltage‐dependent calcium channel (VDCC) inhibitor, and glyburide, an ATP‐regulated potassium channel (K(+) (ATP)) inhibitor, inhibit oxLDL‐induced MCP‐1 release. Potassium efflux and influx counterbalance maintains the negative potential of macrophages to open calcium channels, and our results suggest that oxLDL actually induces the closing of potassium influx channel – inward rectifier channel (K(ir)) and ensuing the opening of calcium channel. ERK MAPK inhibitor PD98059 inhibits oxLDL‐induced Ca(2+)/K(ir) channel alterations. The interfering of oxLDL‐induced MCP‐1 release by its monoclonal antibody is through its FcγRIIB (CD32). Using blocking antibodies against FcγRI (CD64), FcγRIIB (CD32) and FcγRIII (CD16), only CD32 blocking antibody was found to reverse the inhibitory effect of oxLDL antibody on oxLDL‐induced MCP‐1 release. Interestingly, oxLDL antibody specifically inhibits oxLDL‐induced ERK MAPK activation and ensuing Ca(2+)/K(ir) channel alterations, and MCP‐1 release. Thus, we found a molecular mechanism of oxLDL antibody on inhibition of oxLDL‐induced ERK MAPK pathway and consequent MCP‐1 release. |
format | Online Article Text |
id | pubmed-5387129 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53871292017-05-01 oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow Su, Jinyu Zhou, Hui Liu, Xianyan Nilsson, Jan Fredrikson, Gunilla Nordin Zhao, Ming J Cell Mol Med Original Articles oxLDL peptide vaccine and its antibody adoptive transferring have shown a significantly preventive or therapeutic effect in atherosclerotic animal model. The molecular mechanism behind this is obscure. Here, we report that oxLDL induces MCP‐1 release in monocytes/macrophages through their TLR‐4 (Toll‐like receptor 4) and ERK MAPK pathway and is calcium/potassium channel‐dependent. Using blocking antibodies against CD36, TLR‐4, SR‐AI and LOX‐1, only TLR‐4 antibody was found to have an inhibitory effect and ERK MAPK‐specific inhibitor (PD98059) was found to have a dramatic inhibitory effect compared to inhibitors of other MAPK group members (p38 and JNK MAPKs) on oxLDL‐induced MCP‐1 release. The release of cytokines and chemokines needs influx of extracellular calcium and imbalance of efflux of potassium. Nifedipine, a voltage‐dependent calcium channel (VDCC) inhibitor, and glyburide, an ATP‐regulated potassium channel (K(+) (ATP)) inhibitor, inhibit oxLDL‐induced MCP‐1 release. Potassium efflux and influx counterbalance maintains the negative potential of macrophages to open calcium channels, and our results suggest that oxLDL actually induces the closing of potassium influx channel – inward rectifier channel (K(ir)) and ensuing the opening of calcium channel. ERK MAPK inhibitor PD98059 inhibits oxLDL‐induced Ca(2+)/K(ir) channel alterations. The interfering of oxLDL‐induced MCP‐1 release by its monoclonal antibody is through its FcγRIIB (CD32). Using blocking antibodies against FcγRI (CD64), FcγRIIB (CD32) and FcγRIII (CD16), only CD32 blocking antibody was found to reverse the inhibitory effect of oxLDL antibody on oxLDL‐induced MCP‐1 release. Interestingly, oxLDL antibody specifically inhibits oxLDL‐induced ERK MAPK activation and ensuing Ca(2+)/K(ir) channel alterations, and MCP‐1 release. Thus, we found a molecular mechanism of oxLDL antibody on inhibition of oxLDL‐induced ERK MAPK pathway and consequent MCP‐1 release. John Wiley and Sons Inc. 2016-12-20 2017-05 /pmc/articles/PMC5387129/ /pubmed/27995732 http://dx.doi.org/10.1111/jcmm.13033 Text en © 2016 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Su, Jinyu Zhou, Hui Liu, Xianyan Nilsson, Jan Fredrikson, Gunilla Nordin Zhao, Ming oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow |
title | oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow |
title_full | oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow |
title_fullStr | oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow |
title_full_unstemmed | oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow |
title_short | oxLDL antibody inhibits MCP‐1 release in monocytes/macrophages by regulating Ca(2+)/K(+) channel flow |
title_sort | oxldl antibody inhibits mcp‐1 release in monocytes/macrophages by regulating ca(2+)/k(+) channel flow |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387129/ https://www.ncbi.nlm.nih.gov/pubmed/27995732 http://dx.doi.org/10.1111/jcmm.13033 |
work_keys_str_mv | AT sujinyu oxldlantibodyinhibitsmcp1releaseinmonocytesmacrophagesbyregulatingca2kchannelflow AT zhouhui oxldlantibodyinhibitsmcp1releaseinmonocytesmacrophagesbyregulatingca2kchannelflow AT liuxianyan oxldlantibodyinhibitsmcp1releaseinmonocytesmacrophagesbyregulatingca2kchannelflow AT nilssonjan oxldlantibodyinhibitsmcp1releaseinmonocytesmacrophagesbyregulatingca2kchannelflow AT fredriksongunillanordin oxldlantibodyinhibitsmcp1releaseinmonocytesmacrophagesbyregulatingca2kchannelflow AT zhaoming oxldlantibodyinhibitsmcp1releaseinmonocytesmacrophagesbyregulatingca2kchannelflow |